Cargando…
Severe late‐onset neutropenia induced by ocrelizumab in a multiple sclerosis patient: A case report
Ocrelizumab is a recombinant humanized antibody targeted against CD‐20 molecule, which was approved for the treatment of relapsing and primary progressive multiple sclerosis. Common adverse events of ocrelizumab include infusion‐related reactions like rash, pruritus, and flushing. Late‐onset neutrop...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8770231/ https://www.ncbi.nlm.nih.gov/pubmed/35079395 http://dx.doi.org/10.1002/ccr3.5299 |